Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-010: Adjuvant MK-7684A vs pembrolizumab in high-risk stage II–IV melanoma
jRCT2031230099Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab + pembrolizumab and pembrolizumab in cutaneous melanoma (CM) (2 arms), sponsored by Merck & Co. Primary endpoint: Recurrence-Free Survival (RFS). Started May 2023; status: completed.
02
Drugs
vibostolimab + pembrolizumabpembrolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on jRCT2031230099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230099.